Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired... see more

Recent & Breaking News (TSXV:KNE)

Kane Biotech Announces Third Quarter 2024 Financial Results

GlobeNewswire 19 hours ago

Kane Biotech Announces Change in US Distribution Partner for revyve(TM) Antimicrobial Wound Gel

GlobeNewswire 2 days ago

Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024

GlobeNewswire 7 days ago

Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel

GlobeNewswire November 14, 2024

Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement

GlobeNewswire November 14, 2024

Canadian Investment Regulatory Organization Trade Resumption - KNE

Canada NewsWire November 12, 2024

Kane Biotech Announces Agreement to Acquire FB Dermatology

GlobeNewswire November 12, 2024

Canadian Investment Regulatory Organization Trading Halt - KNE

Canada NewsWire November 12, 2024

Kane Biotech Announces Donation of revyve(TM) Antimicrobial Wound Gel to Ukraine

GlobeNewswire October 23, 2024

Kane Biotech Announces Exclusive Distribution Agreement With XSONX

GlobeNewswire October 17, 2024

Kane Biotech to Participate in a Multinational Corporate Collaboration Project

GlobeNewswire October 3, 2024

Kane Biotech Announces Attendance at Upcoming Wound Care Conferences

GlobeNewswire September 26, 2024

Kane Biotech Announces Exercise of Warrants

GlobeNewswire September 12, 2024

Kane Biotech Announces Second Quarter 2024 Financial Results

GlobeNewswire August 29, 2024

Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations

GlobeNewswire August 29, 2024

Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve(TM) Antimicrobial Wound Gel

GlobeNewswire August 28, 2024

Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 - Conference Call to Follow

GlobeNewswire August 22, 2024

Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve(TM) Antimicrobial Wound Gel

GlobeNewswire August 22, 2024

Kane Biotech Receives Funding Support to Expand the revyve(TM) Antimicrobial Wound Gel Family

GlobeNewswire August 13, 2024

Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve(TM) Antimicrobial Wound Gel

GlobeNewswire July 23, 2024